Advertisement

Topics

ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC ...

07:30 EDT 11 Sep 2017 | BioMedReports - Blog

The open-label, single-arm, dose-escalation study evaluated the safety, pharmacokinetics, maximum tolerated dose, and anti-tumor activity of EPI-506 in men with end-stage mCRPC who have progressed

Read more...

Original Article: ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC ...

NEXT ARTICLE

More From BioPortfolio on "ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC ..."

Quick Search
Advertisement